Shire receives US FDA complete response letter for Intuniv
This article was originally published in Scrip
Executive Summary
The US FDA has issued a complete response letter to Shire for its non-stimulant attention deficit hyperactivity disorder (ADHD) candidate Intuniv (guanfacine) extended release.